CNTA

Centessa Pharmaceuticals PLC ADR · NASDAQ

Performance

-3.91%

1W

+44.19%

1M

+67.26%

3M

+66.03%

6M

+41.83%

YTD

+220.74%

1Y

Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Investment Analysis Report: CNTA

Overview

In this investment analysis report, we will delve into the financial statements of CNTA, a company in the Health Technology sector specializing in Pharmaceuticals. We will analyze the Balance Sheets, Income Statements, and Cashflow Statements to gain insights into the company's financial health, growth p...

See more ...

Technical Analysis of CNTA 2024-02-23

Overview:

In analyzing the technical indicators for CNTA over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible stock price movement. By examining key indicators such as moving averages, MACD, RSI, Bollinger Bands, and volume-related metrics, we aim to offe...

See more ...

Recent News & Updates